Why the study?
Despite the high prevalence of HFpEF, no evidence-based guidelines for its management have been generated, and further investigations are needed to elucidate the exact mechanisms underlying HFpEF and the immune-pathogenesis of cardiac fibrosis.
This review highlights the potential pro-inflammatory and profibrotic roles of macrophages in the pathogenesis of HFpEF, suggesting a need for further mechanistic and clinical investigations.
Answers are grounded in this paper and cite their sources.
Highlights macrophages as potential therapeutic target in HFpEF; leaves open whether modulating inflammation improves remodeling or outcomes.
The prevalence of heart failure (HF) with preserved ejection fraction (HFpEF) is higher than that of HF with reduced/midrange ejection fraction (HFrEF/HFmrEF). However, no evidence-based guidelines for managing HFpEF have been generated. The current body of knowledge indicates that fibrosis and inflammation are important components of the cardiac remodeling process in HFpEF. In addition, macrophages potentially play an important role in pro-inflammatory and profibrotic processes in HFpEF patients, whereas HFpEF comorbidities could be a driving force for systemic microvascular inflammation and endothelial dysfunction. Under such circumstances, macrophages reportedly contribute to inflammation and fibrosis through 3 phases namely, inflammation, repair, and resolution. Signal transduction pathway-targeted therapies using animal experiments have generated important discoveries and breakthroughs for understanding the underlying mechanisms of HFpEF. However, only a handful of studies have reported promising results using human trials. Further investigations are therefore needed to elucidate the exact mechanisms underlying HFpEF and immune-pathogenesis of cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
Jinlian Shen (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: